Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: A non-internalised CD38-binding radiolabelled single-domain antibody fragment to monitor and treat multiple myeloma

Fig. 3

a Ex vivo biodistribution of 99mTc-labelled sdAbs in RPMI 8226 CD38+ tumour-bearing mice based on dissection data at 1 h p.i. and expressed as % IA/g (data from these results are included in Additional file 1: Table 1). b In vivo biodistribution of the radiolabelled sdAbs injected in mice expressed as % IA/cc. Data shown in Additional file 1: Table 3. Data are mean ± standard deviation of three mice/sdAb. A radiolabelled irrelevant non-targeting sdAb was used as negative control. c Sagittal and transversal view on fused whole-body and tumour-focused μSPECT/CT acquisitions 1 h p.i. of intravenously injected 99mTc-H6-2F8, 99mTc-H6-1053, 99mTc-H6-551 and non-targeting 99mTc-H6-CTRL in MM mice. One representative of each group is shown. Green arrows indicate tumour uptake, while the yellow and pink arrows indicate renal and urinary bladder uptake, respectively. NIH + white colour scale is used, and images are normalised to the activity at the time of acquisition and equally scaled down to 4% relative to maximum activity in image. For all CD38 sdAbs, the following observation can be made: a non-specific uptake by the kidneys, a tumour site-specific accumulation and a background radioactivity level in most vital organs, albeit at different levels depending on the sdAb. Tumour-to-organ ratios were calculated and are described in Additional file 1: Table 2

Back to article page